*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
Recently, the 2024 Misi Conference (China Medical and Health Industry Symbiosis Conference), organized by the industry's authoritative medical and health information platform MENET, was grandly held in Huzhou, Zhejiang, under the theme "Tenacity·Enlightenment of the New Stage". At the conference, the "2023 Top 100 Innovation List Series for Biopharmaceutical Enterprises in China" was officially released. Genuine Biotech once again made it to the "Top 30 Innovative Small-Molecule Pharmaceutical Enterprises in China", marking the third consecutive year since 2021 that the company has received this honor.
Looking back on 2023, Genuine Biotech achieved our expected operational targets, with the company's development thriving and advancing steadily.
The 36th "World AIDS Day" was celebrated on Dec. 1, 2023 under the theme "Let Communities Lead". Highly active antiretroviral therapy (HAART) has significantly improved the anti-HIV efficacy, contributing to a marked enhancement of patients' quality of life and prognosis.
Recently, China Times announced the prestigious list of 2023 Golden Cane Award winners in Beijing. Genuine Biotech, by virtue of its outstanding innovation capacity and pioneering R&D achievements, received the prize of "Top 10 Innovative Biotech Companies of the Year".
On Sep. 19, 2023, Genuine Biotech announced the appointment of Dr. James He as Senior Vice President and Chief Medical Officer (CMO). Dr. He will lead the clinical and registration team, and assume the responsibility for the product pipeline strategy, clinical project planning and operations, product registration and team construction.
Recently, the award ceremony for the "Henan Socially Responsible Enterprise of 2022 and Entrepreneur with Outstanding Social Contribution" was grandly held in Zhengzhou. Genuine Biotech was honored with the "2022 Annual Award of Henan Socially Responsible Enterprise".
Recently, the award ceremony for the "Henan Socially Responsible Enterprise of 2022 and Entrepreneur with Outstanding Social Contribution" was grandly held in Zhengzhou. Genuine Biotech was honored with the "2022 Annual Award of Henan Socially Responsible Enterprise".
Recently, researchers from Shanghai uploaded a preprint to the preprint server medRxiv. Among severely and critically ill patients with COVID-19 who received one or more therapeutic interventions, treatment with Azvudine had a 99.8% probability of improving 2-month survival compared with the control.
On May 12, the high-profile BEYOND Awards 2023 ceremony was held in Macao. After comprehensive consideration of multiple dimensions such as technical level, commercial value, and innovation value by the expert panel, the COVID-19 Oral Drug Azvudine won the BEYOND Awards Life Science Innovation Award.
On Apr. 19, Wan Yuanhao and He Binyuan, vice presidents of Genuine Biotech, made a team visit to the Third People's Hospital of Shenzhen (hereinafter referred to as the "TPHSZ") and had in-depth conversations with Prof. Lu Hongzhou, president of the hospital and a fellow of American Academy of Microbiology. In hope of satisfying unmet global clinical needs with safer and more efficient treatment options, both parties agreed to seek closer cooperation in the antiviral field.
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
